• Home
  • Who we are
    • Overview
    • Team
    • Board
    • Founders
  • Approach
  • Pipeline
    • Overview
    • BGT-OTCD
    • BGT-DTDS
    • BGT-NPC
    • BGT-INAD
  • News
  • Careers
  • Contact
  • Menu Menu
  • LinkedIn

BGT-DTDS for Dopamine Transporter Deficiency Syndrome (DTDS) and Parkinson’s Disease

BGT-DTDS is a neuron-targeted AAV2 investigational gene therapy designed to provide a potentially curative solution to DTDS patients following a one-time intra-brain injection to the substantia nigra and ventral tegmental area. We are also exploring the application of BGT-DTDS in Parkinson’s disease. AAV2 for intra-parenchymal administration was selected for its success in other mid-brain neurological disorders such as Aromatic l-amino acid decarboxylase deficiency (AADC) and Parkinson’s disease.

Dopamine Transporter Deficiency Syndrome (DTDS)

Disease Characteristics: DTDS is a rare, autosomal recessive childhood neurological disorder with significant disease burden, characterised by a severe parkinsonian movement disorder. DTDS results from biallelic mutations in the SLC6A3 which encodes the dopamine transporter (“DAT”), a key protein regulating dopaminergic signalling. Dopamine re-uptake by DAT is the principal mechanism by which dopamine is removed and recycled from synapses. Mutations in SLC6A3 result in DAT dysfunction and major dysregulation of dopamine neurotransmission, leading to hyperkinetic movement disorders in the early stages of the disease, and then evolution of parkinsonism-like features (slowing of voluntary movements, loss of facial expression, tremor, stiffness) and eye movement disorders such as oculogyric crises. The disease is often fatal in childhood to teenage years due to unexplained death in sleep or respiratory failure.

Unmet Need: There are currently no disease-modifying treatments or approved therapies for DTDS, and patients derive little clinical benefit from available symptom control medications.

Epidemiology: The disease is currently poorly diagnosed, due to symptoms similarity with other movement disorders including cerebral palsy, and the number of patients with the condition is unknown.

Program status

BGT-DTDS has completed preclinical efficacy studies in DTDS and we are currently preparing for a first-in-human clinical trial. We are also initiating an evaluation of BGT-DTDS in Parkinson’s disease in 2023.

BGT-DTDS has been granted orphan drug designation for the treatment of DTDS by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

BGT-DTDS publications

Ng et al. Sci Transl Med May 2021 19;13(594)

Other relevant publications

Kurian et al. Lancet Neurol. January 2011 10(1):54-62

Su et al. Mol Ther August 2010 Vol. 18 no. 8, 1490–1495

San Sebastian et al. Mol Ther October 2014 1404

Lonser et al. J Neurosurg July 2020 134:1751–1763

Pearson et al. Nat Commun July 2021 12:4251

  • Pipeline
  • BGT-OTCD
  • BGT-DTDS
  • BGT-NPC
  • BGT-INAD

  • Home
  • Who we are
  • Approach
  • Pipeline
  • News
  • Careers
  • Contact
Bloomsbury
LinkedIn
@2022 Bloomsbury Genetic Therapies
  • Privacy
  • Cookie Policy
  • Terms and Conditions
Website by FisherPaul
  • Home
  • Who we are
  • Approach
  • Pipeline
  • News
  • Careers
  • Contact
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

AcceptDo not acceptSettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our privacy settings in detail on our Privacy Policy Page.

Privacy
Accept settingsHide notification only
X